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ontinuous Positive
irway Pressure and
ncreased Ejection
raction in Heart Failure
nd Obstructive Sleep Apnea
s There a Metabolic Cost or Benefit?*
anithaya Chareonthaitawee, MD, FACC,
irend Somers, MD, DPHIL, FACC
ochester, Minnesota
espite many advances in the treatment of heart failure
HF) over the past several decades, mortality remains high
1). Recent clinical trials of newer pharmacologic agents
ave reported only limited impact on the high residual
ortality of optimally treated HF patients and underscore
he need for additional novel treatment strategies (2). The
oexistence of obstructive sleep apnea (OSA) and its adverse
mplications in HF patients are increasingly recognized and
ighlight an important therapeutic consideration (2). Treat-
ent of OSA by continuous positive airway pressure
CPAP) has many salutary effects that may benefit cardiac
unction, including a reduction in nocturnal and daytime
ympathetic nervous system activation and attenuation of
ypoxic episodes (2). The prevalence of OSA and HF and
heir comorbidity are expected to increase with the progres-
ive aging of the population and the obesity epidemic (3). It
s therefore important to define whether and how treatment
f OSA affects cardiac function in HF patients.
See page 450
Recent data suggest that OSA is associated with left
entricular (LV) systolic dysfunction and may lead to
rogression of HF or refractoriness to therapy via several
echanisms, including: 1) extremes of negative intratho-
acic pressure, leading to an increase in LV afterload and a
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oncepts and is a co-investigator on a grant for the Res Med Foundation. He has also
eceived an honorarium for speaking at a meeting sponsored by Res Med.ecrease in LV preload; 2) hypoxia, which is cardiotoxic and
ay impair cardiac contractility; and 3) sympathetic activa-
ion producing intermittent surges in blood pressure (4),
urther increasing afterload and wall stress. Several small
tudies have demonstrated an improvement in LV ejection
raction with the use of CPAP in patients with OSA and
V systolic HF (5–7). Although the benefits of CPAP
herapy are becoming apparent in HF patients, the precise
echanisms underlying this improvement in cardiac func-
ion are not well understood. Given the key role of
echano-energetic uncoupling in HF (8), a clinically rele-
ant question is whether a metabolic cost is incurred for this
mprovement. This is especially important because there are
o data addressing whether CPAP therapy of OSA in HF
as any effect on mortality. Heart failure therapies that
mprove cardiac function at the expense of cardiac efficiency,
uch as inotropic agents, are associated with poorer out-
omes (9). In contrast, HF therapies that improve cardiac
unction while preserving myocardial efficiency, such as
eta-blockers and angiotensin-converting enzyme inhibi-
ors, are associated with improved outcomes (10,11).
In this issue of the Journal, Yoshinaga et al. (12) examine
he effects of short- and long-term (6-week) nocturnal
PAP therapy on myocardial energy expenditure assessed
y C-11 acetate positron emission tomography (PET) and
chocardiography in 7 patients with symptomatic moderate
V systolic dysfunction and concomitant OSA. The PET
racer C-11 acetate, a simple 2-carbon carboxylic acid, is
aken up by the myocardium and rapidly converted to acetyl
oenzyme A (13). Because of tight coupling of the tricar-
oxylic acid cycle and oxidative metabolism, myocardial
urnover of C-11 acetate reflects overall flux in the tricar-
oxylic acid cycle and provides an estimate of myocardial
xidative metabolism. In this study, longer-term CPAP
ignificantly increased LVEF and tended to decrease LV
xidative metabolism while maintaining stroke volume in-
ex (SVI), thereby significantly improving myocardial effi-
iency. These changes were evident even though blood
ressure and heart rate were not reduced by CPAP. In the
ve HF patients without OSA and without CPAP therapy
ho served as controls, there were no significant changes in
ny of the measurements between baseline and follow-up.
Because LVEF is a predictor of survival (14), these data
uggest the potential for improved outcome with this
herapy in patients with concomitant HF and OSA. The
dditional longer-term energy-sparing effects of CPAP may
lso be favorable. In some aspects, the effects of CPAP may
e analogous to the chronic effects of beta blockade in HF,
hich also improves cardiac function while maintaining
avorable myocardial energetics (10,15). However, the ef-
ects of CPAP are achieved non-pharmacologically by
educing afterload and increasing preload, thereby lowering
xygen demand and increasing oxygen supply, and by
ttenuating sympathetic activation (2).
i
p
l
Y
C
c
w
w
a
w
o
w
m
H
r
g
i
m
a
m
d
t
i
o
p
i
N
g
E
t
t
a
o
e
w
c
d
h
s
r
t
k
i
d
c
c
m
i
e
s
s
b
i
w
n
s
R
C
s
R
1
1
1
1
1
1
1
1
460 Chareonthaitawee and Somers JACC Vol. 49, No. 4, 2007
Editorial Comment January 30, 2007:459–60Although CPAP therapy is a promising strategy for
mproving LV function, and perhaps even survival, in
atients with coexistent HF and OSA, several limitations
essen our enthusiasm until more data are available. First,
oshinaga et al. (12) noted only very modest changes with
PAP in a small group of 7 patients, all male, with
oexistent HF and OSA. Second, the control population
as a group of patients with HF but without OSA who
ere mostly not obese, had predominantly ischemic HF,
nd did not receive CPAP. In the CPAP-treated patients
ith co-existent HF and OSA, most patients were morbidly
bese, and both ischemic and nonischemic HF etiologies
ere present. As the authors point out, the response of
yocardial energetics to CPAP may differ depending on
F etiology. These factors underscore the need for larger
andomized trials of patients with HF and OSA. Third,
iven the central role of PET C-11 acetate measurements
n this study, factors that might affect the measurement of
yocardial oxidative metabolism should be considered. The
ccuracy of exponential fitting of myocardial C-11 acetate
ay be affected by the rate of delivery of tracer to the heart
uring image acquisition (16). Slower initial tracer delivery
o the myocardium and more tracer recirculation may result
n slower clearance rates and lower estimates of myocardial
xidative metabolism. This effect is expected to be more
ronounced with mono-exponential fitting, which was used
n this study, as opposed to bi-exponential fitting (17).
evertheless, the impact of this approach was likely small,
iven the moderate severity of the LV systolic dysfunction.
xponential fitting may also be affected by spillover from
he blood or lungs (18). The latter may be significant owing
o increased lung tracer activity in patients with symptom-
tic HF and may also lead to underestimation of myocardial
xidative metabolism. Changes in fluid status and pleural
ffusion between the baseline and follow-up PET scans
ould be associated with altered lung tracer activity, which
ould influence the results. Last, myocardial efficiency is
erived from a combination of SVI, systolic blood pressure,
eart rate, and myocardial oxidative metabolism. In this
tudy, measurement of SVI was obtained by echocardiog-
aphy, which may have limited acoustic windows in the
reatment group, where body mass index averaged 36.5
g/m2, but less so in the control group, where body-mass
ndex averaged 30.3 kg/m2. Another disadvantage of this
ual-imaging approach is that differences in hemodynamic
onditions between the 2 imaging sessions may affect the
alculation of myocardial efficiency.
In any event, it is still unknown whether these improve-
ents in cardiac function and efficiency will translate into
mprovements in cardiovascular outcomes. Functional ben-
fits of CPAP, and improvements in surrogates of survival,
uch as ejection fraction, have been documented in several
mall series. Although the interesting observations reported
y Yoshinaga et al. (12) provide further basis for expecting
mproved outcomes with CPAP therapy in HF patients
1ith OSA, carefully designed large randomized trials are
eeded to clarify the true effects of CPAP therapy on
urvival in patients with HF and OSA.
eprint requests and correspondence:Dr. Virend Somers, Mayo
linic, 200 First Street SW, Rochester, Minnesota 55905. E-mail:
omers.virend@mayo.edu.
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